Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR51
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**AR51** was a Merck investigational liquid hexavalent pediatric combination vaccine formulation evaluated in Phase 2 infant studies. The AR51 (12, 10) formulation contained 12 micrograms of *Haemophilus influenzae* type b polyribosylribitol phosphate conjugated to tetanus toxoid and 10 micrograms of recombinant hepatitis B surface antigen, together with diphtheria toxoid, tetanus toxoid, five-component acellular pertussis vaccine, and inactivated poliovirus types 1, 2, and 3. It was administered intramuscularly to induce protective active immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive *H. influenzae* type b disease. AR51 is distinct from the later PR5I/V419 formulation marketed as Vaxelis, which uses PRP-OMPC rather than the PRP-tetanus-toxoid Hib conjugate used in AR51. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT00551629/))
- Brand names
- Vaxelis
- Other names
- DTaP-IPV-Hib-HepB vaccine (AR51 formulation)hexavalent vaccine AR51
02
Targets
HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on AR51.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR51.